WO2002053516A3 - Derives de la n(phenylsulfonyl)glycine et leur utilisation en therapeutique - Google Patents

Derives de la n(phenylsulfonyl)glycine et leur utilisation en therapeutique Download PDF

Info

Publication number
WO2002053516A3
WO2002053516A3 PCT/FR2002/000033 FR0200033W WO02053516A3 WO 2002053516 A3 WO2002053516 A3 WO 2002053516A3 FR 0200033 W FR0200033 W FR 0200033W WO 02053516 A3 WO02053516 A3 WO 02053516A3
Authority
WO
WIPO (PCT)
Prior art keywords
phenylsulphonyl
therapeutic use
glycine derivatives
glycine
derivatives
Prior art date
Application number
PCT/FR2002/000033
Other languages
English (en)
Other versions
WO2002053516A2 (fr
Inventor
Martine Barth
Michel Bondoux
Christophe Matt
Pierre Dodey
Jean-Michel Luccarini
Jean-Luc Paquet
Didier Pruneau
Original Assignee
Fournier Lab Sa
Martine Barth
Michel Bondoux
Christophe Matt
Pierre Dodey
Jean-Michel Luccarini
Jean-Luc Paquet
Didier Pruneau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0206159-7A priority Critical patent/BR0206159A/pt
Priority to US10/451,617 priority patent/US20040063725A1/en
Priority to SK828-2003A priority patent/SK8282003A3/sk
Priority to EP02710082A priority patent/EP1351928A2/fr
Priority to PL02365219A priority patent/PL365219A1/xx
Priority to KR10-2003-7008532A priority patent/KR20030070080A/ko
Priority to IL15656502A priority patent/IL156565A0/xx
Priority to MXPA03006093A priority patent/MXPA03006093A/es
Application filed by Fournier Lab Sa, Martine Barth, Michel Bondoux, Christophe Matt, Pierre Dodey, Jean-Michel Luccarini, Jean-Luc Paquet, Didier Pruneau filed Critical Fournier Lab Sa
Priority to HU0402507A priority patent/HUP0402507A2/hu
Priority to CA002434124A priority patent/CA2434124A1/fr
Priority to JP2002554636A priority patent/JP2004534729A/ja
Publication of WO2002053516A2 publication Critical patent/WO2002053516A2/fr
Publication of WO2002053516A3 publication Critical patent/WO2002053516A3/fr
Priority to NO20033099A priority patent/NO20033099L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/16—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés de la N(phénylsulfonyl)glycyl-glycine, définis par la formule (I) et la description, ainsi que leur procédé de préparation et leur utilisation en thérapeutique.
PCT/FR2002/000033 2001-01-08 2002-01-07 Derives de la n(phenylsulfonyl)glycine et leur utilisation en therapeutique WO2002053516A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IL15656502A IL156565A0 (en) 2001-01-08 2002-01-07 N-(phenylsulphonyl) glycine derivatives and their therapeutic use
SK828-2003A SK8282003A3 (en) 2001-01-08 2002-01-07 N-(phenylsulphonyl)glycine derivatives and their therapeutic use
EP02710082A EP1351928A2 (fr) 2001-01-08 2002-01-07 Derives de la n-(phenylsulfonyl)-glycine et leur utilistaion en therapeutique
PL02365219A PL365219A1 (en) 2001-01-08 2002-01-07 N(phenylsulphonyl)glycine derivatives and their therapeutic use
KR10-2003-7008532A KR20030070080A (ko) 2001-01-08 2002-01-07 엔-(페닐술포닐) 글리신 유도체와 이들의 치료적 용도
BR0206159-7A BR0206159A (pt) 2001-01-08 2002-01-07 Derivados da n(fenilsulfonil)glicina e sua utilização terapêutica
MXPA03006093A MXPA03006093A (es) 2001-01-08 2002-01-07 Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
US10/451,617 US20040063725A1 (en) 2001-01-08 2002-01-07 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use
HU0402507A HUP0402507A2 (hu) 2001-01-08 2002-01-07 N(fenilszulfonil)glicin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
CA002434124A CA2434124A1 (fr) 2001-01-08 2002-01-07 Derives de la n(phenylsulfonyl)glycine et leur utilisation en therapeutique
JP2002554636A JP2004534729A (ja) 2001-01-08 2002-01-07 Ｎ−（フェニルスルホニル）グリシン誘導体とその治療への利用
NO20033099A NO20033099L (no) 2001-01-08 2003-07-07 N-(fenylsulfonyl)glycin-derivater og deres terapeutiske anvendelse

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01/00195 2001-01-08
FR0100195A FR2819254B1 (fr) 2001-01-08 2001-01-08 Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques

Publications (2)

Publication Number Publication Date
WO2002053516A2 WO2002053516A2 (fr) 2002-07-11
WO2002053516A3 true WO2002053516A3 (fr) 2002-10-10

Family

ID=8858600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/000033 WO2002053516A2 (fr) 2001-01-08 2002-01-07 Derives de la n(phenylsulfonyl)glycine et leur utilisation en therapeutique

Country Status (17)

Country Link
US (1) US20040063725A1 (fr)
EP (1) EP1351928A2 (fr)
JP (1) JP2004534729A (fr)
KR (1) KR20030070080A (fr)
CN (1) CN1484633A (fr)
BR (1) BR0206159A (fr)
CA (1) CA2434124A1 (fr)
CZ (1) CZ20031715A3 (fr)
FR (1) FR2819254B1 (fr)
HU (1) HUP0402507A2 (fr)
IL (1) IL156565A0 (fr)
MX (1) MXPA03006093A (fr)
NO (1) NO20033099L (fr)
PL (1) PL365219A1 (fr)
RU (1) RU2003120798A (fr)
SK (1) SK8282003A3 (fr)
WO (1) WO2002053516A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230382B1 (hu) * 2001-02-24 2016-03-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként
WO2003070229A2 (fr) * 2002-02-22 2003-08-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Utilisation d'inhibiteurs de proteinases pour le traitement de maladies auto-immunes
FR2840897B1 (fr) * 2002-06-14 2004-09-10 Fournier Lab Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
FR2853648B1 (fr) * 2003-04-11 2006-08-18 Fournier Lab Sa Nouveaux derives de benzenesulfonamides et leur utilisation en therapeutique
DE602004021358D1 (de) * 2003-03-25 2009-07-16 Fournier Lab Sa Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2007076875A2 (fr) * 2006-01-06 2007-07-12 Aarhus Universitet Composes agissant sur le transporteur de la serotonine
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
DE102006039003A1 (de) * 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen
US20110077231A1 (en) * 2007-08-14 2011-03-31 Boehringer Ingelheim International Gmbh Compounds
WO2009021944A1 (fr) * 2007-08-14 2009-02-19 Boehringer Ingelheim International Gmbh Nouveaux composés
EP2025675A1 (fr) * 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamides ayant activité analgésique
WO2009021758A1 (fr) * 2007-08-14 2009-02-19 Boehringer Ingelheim International Gmbh Arylsulfonamides ayant un effet analgésique
EP2025668A1 (fr) * 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamides ayant activité analgésique
EP2025673A1 (fr) * 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamides ayant activité analgésique
ES2733348T3 (es) * 2007-08-17 2019-11-28 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
GB0807828D0 (en) * 2008-04-29 2008-06-04 Vantia Ltd Aminopyridine derivatives
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CA2735562C (fr) * 2008-08-15 2017-10-17 Boehringer Ingelheim International Gmbh Inhibiteurs de dpp-4 servant a la guerison d'une plaie
RU2011113823A (ru) 2008-09-10 2012-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
JP2013512229A (ja) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｄｐ−ｉｖ阻害薬による治療
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
EP3725325B1 (fr) 2010-06-24 2023-05-31 Boehringer Ingelheim International GmbH Traitement du diabète
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (fr) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin pour son utilisation dans le traitement de l'albuminurie et des maladies liees au rein
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
CN103965050B (zh) * 2013-02-01 2015-09-30 清华大学 一种卤代芳环类化合物及其制备方法
EP3110449B1 (fr) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Utilisation médicale d'un inhibiteur de dpp-4
MX2018015089A (es) 2016-06-10 2019-05-13 Boehringer Ingelheim Int Combinacion de linagliptina y metformina.

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2508444A1 (fr) * 1981-06-29 1982-12-31 Irceba Nouveaux derives sulfonyle du tryptophane utiles en tant que medicaments et leur procede de preparation
EP0614911A1 (fr) * 1993-02-15 1994-09-14 Sanofi Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant
WO1996040639A1 (fr) * 1995-06-07 1996-12-19 Fournier Industrie Et Sante Derives de benzenesulfonamide comme antagonistes de la bradykinine
WO1997024349A1 (fr) * 1995-12-29 1997-07-10 Fournier Industrie Et Sante Derives de 1-benzenesulfonylpyrrolidine comme antagonistes du recepteur de la bradykinine
WO1997025315A1 (fr) * 1996-01-11 1997-07-17 Sanofi Nouveaux derives de n-(arylsulfonyl)aminoacides ayant une affinite pour les recepteurs de la bradykinine
WO1998003503A1 (fr) * 1996-07-24 1998-01-29 Fournier Industrie Et Sante Derives de n-benzenesulfonyl-l-proline en tant qu'agonistes de la bradykinine b2
WO1998024783A1 (fr) * 1996-12-04 1998-06-11 Fournier Industrie Et Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
WO1999000387A1 (fr) * 1997-06-27 1999-01-07 Fournier Industrie Et Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT84171B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados das n alfa-aril-sulfonilamiminoacil-p- -amidinofenil-alaninamidas, bem como dos seus derivados de sintese e das composicoes farmaceuticas que os contem
PT84170B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados n alfa-substituidos das n alfa-aril-sulfonilaminoacil d-amidinofenil-alaninamidas
DE4206858A1 (de) * 1992-03-05 1993-09-09 Behringwerke Ag Glycopeptid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische mittel
US5714497A (en) * 1993-02-15 1998-02-03 Sanofi Compounds bearing sulphamoyl and amidino radicals, their preparation process and pharmaceutical compositions containing them
EP1364960A4 (fr) * 2001-02-02 2005-05-18 Chugai Pharmaceutical Co Ltd Derives de peptide

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2508444A1 (fr) * 1981-06-29 1982-12-31 Irceba Nouveaux derives sulfonyle du tryptophane utiles en tant que medicaments et leur procede de preparation
EP0614911A1 (fr) * 1993-02-15 1994-09-14 Sanofi Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant
WO1996040639A1 (fr) * 1995-06-07 1996-12-19 Fournier Industrie Et Sante Derives de benzenesulfonamide comme antagonistes de la bradykinine
WO1997024349A1 (fr) * 1995-12-29 1997-07-10 Fournier Industrie Et Sante Derives de 1-benzenesulfonylpyrrolidine comme antagonistes du recepteur de la bradykinine
WO1997025315A1 (fr) * 1996-01-11 1997-07-17 Sanofi Nouveaux derives de n-(arylsulfonyl)aminoacides ayant une affinite pour les recepteurs de la bradykinine
WO1998003503A1 (fr) * 1996-07-24 1998-01-29 Fournier Industrie Et Sante Derives de n-benzenesulfonyl-l-proline en tant qu'agonistes de la bradykinine b2
WO1998024783A1 (fr) * 1996-12-04 1998-06-11 Fournier Industrie Et Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
WO1999000387A1 (fr) * 1997-06-27 1999-01-07 Fournier Industrie Et Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique

Also Published As

Publication number Publication date
NO20033099L (no) 2003-09-02
HUP0402507A2 (hu) 2005-03-29
CZ20031715A3 (cs) 2003-11-12
CN1484633A (zh) 2004-03-24
MXPA03006093A (es) 2005-02-14
SK8282003A3 (en) 2003-12-02
US20040063725A1 (en) 2004-04-01
RU2003120798A (ru) 2004-12-27
JP2004534729A (ja) 2004-11-18
PL365219A1 (en) 2004-12-27
IL156565A0 (en) 2004-01-04
FR2819254A1 (fr) 2002-07-12
FR2819254B1 (fr) 2003-04-18
BR0206159A (pt) 2003-12-23
KR20030070080A (ko) 2003-08-27
NO20033099D0 (no) 2003-07-07
CA2434124A1 (fr) 2002-07-11
WO2002053516A2 (fr) 2002-07-11
EP1351928A2 (fr) 2003-10-15

Similar Documents

Publication Publication Date Title
WO2002053516A3 (fr) Derives de la n(phenylsulfonyl)glycine et leur utilisation en therapeutique
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
HUP0401293A3 (en) Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
HK1078087A1 (en) Process for the preparation of (s,s)-cis-2-benzhydryl-3- benzylaminoquinuclidine
SI1699795T1 (sl) Substituirani 8-piri(mi)dinil-dihidrospiro-(cikloalkilamin)pirimido(1,2a) pirimidin-6-onski derivati
WO2003057163A3 (fr) Preparation d'immunoconjugues
MXPA03008630A (es) Derivados de arilisoxazolinas, procedimientos para su preparacion y su utilizacion como agentes plaguicidas.
IL162316A0 (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition t
AU2003212310A1 (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
MXPA03009206A (es) FORMULACIONES DE 3,7-DIAZABICICLO [3.3.1] COMO COMPUESTOS ANTIARRiTMICOS.
WO2001049654A3 (fr) Derives d'aminomethyle-phenyle-cyclohexane substitues
AU2002330042A1 (en) Process for the preparation of 1,5-diarylpyrazoles
MXPA03009209A (es) Formulaciones de 3,7-diazabiciclo-[3.3.1] como compuestos anti-arritmicos.
IL162188A0 (en) Process for the preparation of Ä1,4,5Ü-oxadiazepine derivatives
AU2002328285A1 (en) Method for producing an essentially chlorite-free, stable, aqueous chlorine-oxygen solution, the chlorine-oxygen solution obtained by means of said method, and the use of the same
ZA200408029B (en) Novel 1,3,5-triazine derivatives as ligands for human adenosine-A3 receptors.
AU2001256674A1 (en) N-(heterocycle-methyl)alkylamine derivative, process for producing the same, andbactericide
AU2003264894A1 (en) Novel method for preparing alpha-glycosylceramides, novel alpha-glycosylceramide derivatives and their uses
AU2003266528A1 (en) Cyclic amine compound, process for producing the same, and use
AU2002241271A1 (en) Method for preparing 7-quinolinyl-3,5-dihydroxyhept-6-enoate
AU2002365852A1 (en) Processes for preparing %a-d-ribofuranose derivatives
AU2002233181A1 (en) Novel, 2,5-diazabicyclo[2.2.1]heptane derivatives
IL159965A0 (en) Novel 2,4-diaminothiazole derivatives
AU2003221281A1 (en) Benzopyran compounds, process for preparing the same and their use
AU2002333299A1 (en) Isoxazoline derivatives as p, n ligands

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PV2003-1715

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 156565

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200304820

Country of ref document: ZA

Ref document number: 10451617

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002710082

Country of ref document: EP

Ref document number: 1020037008532

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1003/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 8282003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/006093

Country of ref document: MX

Ref document number: 2434124

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 10797902

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 028035194

Country of ref document: CN

Ref document number: 2002228139

Country of ref document: AU

Ref document number: 2002554636

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 1020037008532

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2002710082

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2003-1715

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002710082

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2003-1715

Country of ref document: CZ